INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program. METHOD: PASCA is a single-center, interventional cohort study of adult patients who received at least chemotherapy and with a complete remission to a testicular germ cell tumor, primary non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four assessment visits will be scheduled at 1 month (T1), 6 months (T2), 24 months (T3) and 60 months (T4) after completion of treatment. During these visits, 19 complications will be screened and follow-up care will be systematically offered to the health professional concerned by the complication in case of a positive result. The screening will contain the following elements: screening self-questionnaires, quality of life questionnaire, 12 biological parameters, a urinalysis evaluating hematuria, proteinuria, and leukocyturia, a spirometry, an electrocardiogram, 5 tests evaluating physical condition, vital signs and the perimetric measurement between both arms. DISCUSSION: This systematic screening could highlight a number of complications occurring after cancer treatments. Sub-clinical abnormalities and new risk factors could also be identified. This new organization of care could improve the quality of life of adult cancer survivors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of social precariousness
Timeframe: Month 1
Change from Baseline return to work issues incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline cognitive problems incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline anxiety crises incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline depressive events incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline physical deconditioning incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline overweight/obesity incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline chronic pain incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline dermatological disorders incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline gastrointestinal disorders incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline sexual disorders incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline hypogonadism incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from 24 months premature ovarian failure incidence at 60 months
Timeframe: Month 24, Month 60
Change from Baseline osteoporosis incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline chronic kidney failure incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline heart failure incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline coronary heart disease incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline respiratory failure incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60
Change from Baseline hypothyroidism incidence at 60 months
Timeframe: Month 1, Month 6, Month 24, Month 60